Approaching recovery from myalgic encephalomyelitis and chronic fatigue syndrome: Challenges to consider in research and practice.
Devendorf, Andrew R, Jackson, Carly T, Sunnquist, Madison et al. · Journal of health psychology · 2019 · DOI
Quick Summary
This study interviewed 13 doctors who treat ME/CFS to understand the challenges they face when trying to measure whether patients are getting better. The researchers found four main areas that make recovery difficult to assess: differences in how the illness affects people at different ages, the fact that ME/CFS shows up differently in different patients, trouble keeping track of patients over time, and practical difficulties in measuring improvement.
Why It Matters
This study addresses a fundamental gap in ME/CFS research: how to properly define and measure recovery. By identifying real-world challenges that physicians encounter, it provides practical guidance for researchers designing treatment trials and recovery criteria that will be clinically meaningful and scientifically valid for this complex, heterogeneous condition.
Observed Findings
Physicians identified that ME/CFS presentation and recovery potential vary significantly by patient age and lifespan stage.
The disease's heterogeneity—including variable case definitions and different etiological theories—complicates standardized recovery assessment.
Patient follow-up and selection bias represent substantial practical barriers in tracking recovery over time.
Assessment logistics (what measures to use, how to administer them) lack standardization across clinical practice.
Inferred Conclusions
Recovery research in ME/CFS requires methodological approaches that account for population heterogeneity rather than assuming uniform disease presentation.
Clinicians and researchers should establish clear, operationalized recovery criteria before conducting treatment outcome studies.
Future recovery assessments must incorporate strategies to minimize selection bias and maintain longitudinal patient follow-up.
Development of standardized, feasible assessment tools is essential for meaningful comparison across studies and clinical settings.
Remaining Questions
What do ME/CFS patients themselves identify as meaningful markers of recovery, and how do these align with or differ from physician perspectives?
What This Study Does Not Prove
This study does not test any treatments or establish what actually causes recovery in ME/CFS patients. It is a methodological exploration based on physician interviews only, so it does not represent patient experiences or validate any specific recovery definitions. The findings are recommendations for future research design rather than established scientific facts about recovery mechanisms.
How should recovery criteria be modified for different age groups, disease severity levels, or ME/CFS subtypes?
Which specific assessment tools and measurement strategies best balance clinical feasibility with scientific rigor in recovery studies?
How can researchers design studies that minimize selection bias while maintaining adequate follow-up in a population with reduced capacity for participation?